| Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix™ in Combination with CRESTOR® Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
|
(Abbott Laboratories)
|
07-Jun-2008 |
| New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
|
(Abbott Laboratories)
|
03-Jun-2008 |
| Phase III study of investigational TRILIPIX™ (SLV348/ABT-335), in combination with AstraZeneca’s CRESTOR® meets primary endpoints on key lipids
|
(Solvay)
|
02-Jun-2008 |
| Abbott Submits Application for Approval of XIENCE™ V Everolimus Eluting Coronary Stent System in Japan
|
(Abbott Laboratories)
|
02-Jun-2008 |
| Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids
|
(Abbott Laboratories)
|
31-May-2008 |
| Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
|
(Gilead Sciences)
|
29-May-2008 |
| Abbott Presents Long-term Data from Extension Study Showing Adult Crohn’s Patients Treated with HUMIRA® (adalimumab) Maintained Remission
|
(Abbott Laboratories)
|
21-May-2008 |
| Gilead Announces New Letairis(R) (Ambrisentan) Data for the Treatment of Patients With Pulmonary Arterial Hypertension (WHO Group 1) With WHO Functional Class II or III Symptoms
|
(Gilead Sciences)
|
20-May-2008 |
| SkyePharma Announces Presentation of Flutiform™ Phase III Safety Study at ATS in Toronto
|
(SkyePharma)
|
20-May-2008 |
| ZonePerfect Dark Chocolate Nutrition Bars Indulge Chocoholics
|
(Abbott Laboratories)
|
19-May-2008 |
| TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
|
(TAP Pharmaceutical Products)
|
18-May-2008 |
| Abbott Launches Next-Generation StarClose® SE Vascular Closure System
|
(Abbott Laboratories)
|
16-May-2008 |
| Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
|
(Abbott Laboratories)
|
15-May-2008 |
| VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
|
(VIA Pharmaceuticals)
|
15-May-2008 |
| XIENCE™ V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
|
(Abbott Laboratories)
|
14-May-2008 |
| XIENCE™ V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
|
(Abbott Laboratories)
|
13-May-2008 |
| New Abbott Study of Investigational Vicodin CR™ Meets Primary Efficacy Endpoints in Phase III Trial
|
(Abbott Laboratories)
|
08-May-2008 |
| Abbott Scientists Present a New Approach for Treating Attention-Deficit Hyperactivity Disorder
|
(Abbott Laboratories)
|
07-May-2008 |
| Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
|
(AstraZeneca)
|
05-May-2008 |
| Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
|
(AstraZeneca)
|
04-May-2008 |
| Gilead Initiates Letairis(R) (ambrisentan) Phase IV Program
|
(Gilead Sciences)
|
01-May-2008 |
| Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA® for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women
|
(Takeda)
|
30-Apr-2008 |
| Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA(R) for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women
|
(Sucampo Pharmaceuticals)
|
29-Apr-2008 |
| Mylan Announces Final FDA Approval for Trandolapril Tablets
|
(Mylan)
|
29-Apr-2008 |
| GlaxoSmithKline's Volibris (ambrisentan) Receives Authorisation from the European Commission for the Treatment of Functional Class II and III Pulmonary Arterial Hypertension
|
(GlaxoSmithKline)
|
25-Apr-2008 |
| Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline
|
(Abbott Laboratories)
|
25-Apr-2008 |
| Study in JAMA Shows Patients Treated with Abbott's XIENCE™ V Drug Eluting Stent Experience Better Outcomes than Patients Treated with Market-Leading Drug Eluting Stent
|
(Abbott Laboratories)
|
22-Apr-2008 |
| HUMIRA® Received Approval for the Treatment of Rheumatoid Arthritis in Japan
|
(Eisai)
|
16-Apr-2008 |
| Abbott Announces Humira® (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
|
(Abbott Laboratories)
|
16-Apr-2008 |
| SkyePharma Announces Positive Results of Flutiform™ Paediatric Study
|
(SkyePharma)
|
15-Apr-2008 |
| Innovative Diagnostic Instrument Introduced by Abbott for Low- to Mid-Volume Laboratory Market Segment
|
(Abbott Laboratories)
|
15-Apr-2008 |
| Abbott FreeStyle Freedom® Lite Blood Glucose Monitoring System Now Available with No Coding for People With Diabetes
|
(Abbott Laboratories)
|
14-Apr-2008 |
| Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
|
(Advanced Life Sciences)
|
10-Apr-2008 |
| New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
|
(Abbott Laboratories)
|
07-Apr-2008 |
| VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
|
(VIA Pharmaceuticals)
|
04-Apr-2008 |
| Abbott's XIENCE™ V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
|
(Abbott Laboratories)
|
31-Mar-2008 |
| Abbott's Phase III Studies of Investigational TriLipix™ (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
|
(Abbott Laboratories)
|
31-Mar-2008 |
| Landmark Trial ONTARGET® Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-risk Cardiovascular Population
|
(Boehringer Ingelheim)
|
31-Mar-2008 |
| Phase III Studies of Investigational Trilipix™ (SLV348/ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
|
(Solvay)
|
31-Mar-2008 |
| Three Year Follow-up Data Suggest Better Outcomes Were Maintained with the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Brachytherapy in Patients with In-Stent Reblockage
|
(Johnson & Johnson)
|
30-Mar-2008 |
| VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
|
(VIA Pharmaceuticals)
|
20-Mar-2008 |
| FDA Approves Abbott's FreeStyle Navigator® Continuous Glucose Monitoring System
|
(Abbott Laboratories)
|
13-Mar-2008 |
| The Lancet Publishes Results from World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
|
(Abbott Laboratories)
|
13-Mar-2008 |
| Abbott's HUMIRA® (adalimumab) Shows Long-Term Improvement In Fistula Response and Healing Rates In Difficult-to-Treat Patients With Crohn's Disease
|
(Abbott Laboratories)
|
13-Mar-2008 |
| Abbott Receives CE Mark for Smaller-Size XIENCE™ V Drug Eluting Stent
|
(Abbott Laboratories)
|
11-Mar-2008 |
| Ipsen approval marks new wave of gout treatments
|
(Ipsen)
|
25-Feb-2008 |
| GSK's Volibris (ambrisentan) Receives EMEA Positive Opinion for Approval to Treat Class II and II Pulmonary Arterial Hypertension (PAH)
|
(GlaxoSmithKline)
|
22-Feb-2008 |
| Abbott Receives FDA Approval for HUMIRA® (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
|
(Abbott Laboratories)
|
22-Feb-2008 |
| Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
|
(Advanced Life Sciences)
|
19-Feb-2008 |
| Abbott Receives FDA Approval for SIMCOR® (Niaspan® / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
|
(Abbott Laboratories)
|
15-Feb-2008 |
| Sun Pharma Gets USFDA Tentative Approval for Generic Depakote® Delayed Release Tablets
|
(Sun Pharmaceutical Industries)
|
14-Feb-2008 |
| Mylan Restores Availability of Generic Levothyroxine in Florida
|
(Mylan)
|
08-Feb-2008 |
| Medtronic Receives FDA Approval for Endeavor® Zotarolimus-Eluting Coronary Stent System
|
(Medtronic)
|
01-Feb-2008 |
| Abbott Gains Reimbursement for XIENCE(TM) V Drug Eluting Stent in France
|
(Abbott Laboratories)
|
01-Feb-2008 |
| Akorn, Inc. Announces FDA Approval of Calcitriol Injection, 1 mcg/mL and 2 mcg/mL
|
(Akorn)
|
30-Jan-2008 |
| Abbott's Kaletra® and Aluvia® (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
|
(Abbott Laboratories)
|
28-Jan-2008 |
| Teva Announces Tentative Approval of Generic Prevacid® Delayed-release Capsules
|
(Teva Pharmaceutical Industries)
|
23-Jan-2008 |
| Fournier Laboratories Ireland Ltd was Informed of ANDA Filing for Generic TriCor® in the USA
|
(Solvay)
|
23-Jan-2008 |
| Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
|
(Abbott Laboratories)
|
18-Jan-2008 |
| Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
|
(Abbott Laboratories)
|
18-Jan-2008 |
| VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
|
(VIA Pharmaceuticals)
|
07-Jan-2008 |
| TAP Pharmaceutical Products Inc. Filed New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
|
(Takeda)
|
04-Jan-2008 |
| TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
|
(TAP Pharmaceutical Products)
|
03-Jan-2008 |
| Watson Launches Generic Biaxin(R) XL
|
(Watson Pharmaceuticals)
|
03-Jan-2008 |
| Abbott's HUMIRA® Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
|
(Abbott Laboratories)
|
20-Dec-2007 |
| Flutiform™ - Enrolment into Efficacy Trials Completed
|
(SkyePharma)
|
18-Dec-2007 |
| Ugandan Children are Among the First to Receive Abbott's Lower-Strength Aluvia (lopinavir/ritonavir) Tablet
|
(Abbott Laboratories)
|
01-Dec-2007 |
| Sucampo Pharma, Ltd., a Subsidiary of Sucampo Pharmaceuticals, Inc., Announces Start of Phase 2b Study in Japan to Evaluate Lubiprostone for Chronic Idiopathic Constipation
|
(Sucampo Pharmaceuticals)
|
29-Nov-2007 |
| FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
|
(Abbott Laboratories)
|
29-Nov-2007 |
| Eisai Submits NDA Application of KES524 for Obesity Management in Japan
|
(Eisai)
|
29-Nov-2007 |
| Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE(TM) V Drug Eluting Stent to FDA Advisory Committee on Nov. 29
|
(Abbott Laboratories)
|
27-Nov-2007 |
| Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
|
(Abbott Laboratories)
|
16-Nov-2007 |
| Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
|
(Advanced Life Sciences)
|
15-Nov-2007 |
| Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra® (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
|
(Abbott Laboratories)
|
12-Nov-2007 |
| Abbott Research Demonstrates Viability of Combining Antibody Functions to Target Two or More Disease-Causing Processes
|
(Abbott Laboratories)
|
08-Nov-2007 |
| Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA® (adalimumab)
|
(Abbott Laboratories)
|
08-Nov-2007 |
| New Clinical Data Show Solvay’s Fenofibrate Cuts Risk of Main Causes of Vision Loss in Patients With Type 2 Diabetes
|
(Solvay)
|
07-Nov-2007 |
| VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
|
(VIA Pharmaceuticals)
|
06-Nov-2007 |
| Shire Announces Results of Fosrenol® Study in Pre-dialysis CKD Stage 3 & 4 Patients
|
(Shire)
|
06-Nov-2007 |
| Abbott Confirms FDA Advisory Panel to Review XIENCE™ V Drug Eluting Stent on November 29
|
(Abbott Laboratories)
|
05-Nov-2007 |
| Abbott's Investigational SIMCOR® Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
|
(Abbott Laboratories)
|
04-Nov-2007 |
| Flutiform™ - Results of Safety Study
|
(SkyePharma)
|
02-Nov-2007 |
| Bentley Announces Its First Product Approval in France
|
(Bentley Pharmaceuticals)
|
01-Nov-2007 |
| Abbott Launches Fruitified™ ZonePerfect® All-Natural Nutrition Bars
|
(Abbott Laboratories)
|
01-Nov-2007 |
| Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
|
(Abbott Laboratories)
|
01-Nov-2007 |
| Universal Clamp™ Spinal Fixation Systems Added to Abbott's Portfolio of Spinal Devices
|
(Abbott Laboratories)
|
25-Oct-2007 |
| Gilead Announces New Letairis(TM) (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
|
(Gilead Sciences)
|
23-Oct-2007 |
| Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated with Surgery
|
(Abbott Laboratories)
|
23-Oct-2007 |
| FDA Issues Approvable Letter for Stavzor(TM) Delayed Release Valproic Acid Capsules
|
(Noven Pharmaceuticals)
|
23-Oct-2007 |
| Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
|
(Abbott Laboratories)
|
22-Oct-2007 |
| Medtronic Receives CE Mark for Endeavor® Resolute Drug-Eluting Stent
|
(Medtronic)
|
22-Oct-2007 |
| Abbott's XIENCE™ V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
|
(Abbott Laboratories)
|
22-Oct-2007 |
| New Long-Term Data Suggest Clinical Differences in Safety and Efficacy Between CYPHER® Sirolimus-Eluting Coronary Stent and Taxus Stent
|
(Johnson & Johnson)
|
22-Oct-2007 |
| New Study Shows Excellent Outcomes for CYPHER® Sirolimus-Eluting Coronary Stent in Treatment of Completely Blocked Coronary Arteries
|
(Johnson & Johnson)
|
21-Oct-2007 |
| Abbott Scientists Create One Molecule with Two Antibody Functions
|
(Abbott Laboratories)
|
18-Oct-2007 |
| FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia
|
(Shire)
|
17-Oct-2007 |
| FDA Advisory Committee Recommends Medtronic’s Endeavor® Drug-Eluting Stent for Approval
|
(Medtronic)
|
10-Oct-2007 |
| Medtronic to Present Findings from the Comprehensive Endeavor Clinical Experience to FDA Advisory Panel
|
(Medtronic)
|
05-Oct-2007 |
| Critical Therapeutics Initiates Phase II Clinical Trial for Zileuton Injection
|
(Critical Therapeutics)
|
03-Oct-2007 |
| Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
|
(Ranbaxy Laboratories)
|
02-Oct-2007 |
| Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
|
(Abbott Laboratories)
|
02-Oct-2007 |
| Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America
|
(Advanced Life Sciences)
|
02-Oct-2007 |
| Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
|
(Abbott Laboratories)
|
01-Oct-2007 |
| Abbott Initiates Clinical Study to Evaluate Use of RX Herculink® Elite™ Renal Stent System for the Treatment of Renal Artery Stenosis
|
(Abbott Laboratories)
|
25-Sep-2007 |
| Abbott and Eisai Submit Application for Adalimumab, the Only Fully Human Monoclonal Anti-TNF Antibody, to Treat Psoriasis
|
(Eisai)
|
25-Sep-2007 |
| Data from Phase II Study of Gilead's Darusentan in Resistant Hypertension Published in Journal of Clinical Hypertension
|
(Gilead Sciences)
|
24-Sep-2007 |
| The Cypher® Sirolimus-eluting Coronary Stent Outperforms the Taxus Stent in Small Coronary Vessels According to New Clinical Data Analysis Published in the Journal of the American College of Cardiology
|
(Johnson & Johnson)
|
21-Sep-2007 |
| FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
|
(Sucampo Pharmaceuticals)
|
18-Sep-2007 |
| Ligand Announces Positive Preclinical Data on Selective Androgen Receptor Modulator LGD-3303
|
(Ligand Pharmaceuticals)
|
17-Sep-2007 |
| Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
|
(Sucampo Pharmaceuticals)
|
13-Sep-2007 |
| Abbott Launches NutriPals™ Fruit Bars with One Serving of Real Fruit in Every Bar
|
(Abbott Laboratories)
|
12-Sep-2007 |
| Further Update on Flutiform™
|
(SkyePharma)
|
11-Sep-2007 |
| NeuroSearch’s License Partner Abbott Initiates Clinical Phase II Study With ABT-894 in Neuropathic Pain
|
(NeuroSearch)
|
07-Sep-2007 |
| Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
|
(Johnson & Johnson)
|
05-Sep-2007 |
| Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
|
(Johnson & Johnson)
|
04-Sep-2007 |
| Two-Year Outcomes From Large Head-To-Head Clinical Trial Indicate Similar Safety Profile In Diabetic Patients for CYPHER® Sirolimus-Eluting Coronary Stent And Taxus Stent
|
(Johnson & Johnson)
|
04-Sep-2007 |
| Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
|
(Johnson & Johnson)
|
03-Sep-2007 |
| AstraZeneca and Abbott Announce Selection of Next-Generation Fenofibrate (ABT-335) and CRESTOR® Fixed-Dose Combination
|
(AstraZeneca)
|
31-Aug-2007 |
| Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR® Fixed-Dose Combination
|
(Abbott Laboratories)
|
31-Aug-2007 |
| Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
|
(Advanced Life Sciences)
|
21-Aug-2007 |
| FDA Advisory Panel to Review Medtronic’s Endeavor Drug Eluting Stent in October
|
(Medtronic)
|
21-Aug-2007 |
| Ranbaxy Receives US FDA Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
|
(Ranbaxy Laboratories)
|
20-Aug-2007 |
| Jerini Receives EMEA Filing Acceptance of its Marketing Application for Icatibant in the Treatment of Hereditary Angioedema
|
(Jerini)
|
16-Aug-2007 |
| Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
|
(Abbott Laboratories)
|
09-Aug-2007 |
| Flutiform(TM) Progress Update
|
(SkyePharma)
|
06-Aug-2007 |
| Biotest and Abbott Cooperate on a Clinical Trial for the Expansion of the Indication of Cytotect®
|
(Biotest)
|
01-Aug-2007 |
| NeuroSearch’s License Partner Abbott Initiates Clinical Phase I Study With ABT-560
|
(NeuroSearch)
|
31-Jul-2007 |
| Kaletra Pediatric Tablet Filing in Thailand
|
(Abbott Laboratories)
|
27-Jul-2007 |
| Abbott's New Aluvia® (lopinavir/ritonavir) Tablet Approved in Nineteen African Countries
|
(Abbott Laboratories)
|
25-Jul-2007 |
| Abbott Submits E.U. and U.S. Regulatory Filings for New Lower-Strength Kaletra® and Aluvia® (lopinavir/ritonavir) Tablet Suitable for Pediatric Use in HIV/AIDS
|
(Abbott Laboratories)
|
20-Jul-2007 |
| Abbott Enrolls First Patient in World’s First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
|
(Abbott Laboratories)
|
19-Jul-2007 |
| Sucampo Pharmaceuticals Submits SupplementalNew Drug Application for Lubiprostone to Treat Irritable Bowel Syndrome with Constipation
|
(Takeda)
|
12-Jul-2007 |
| Abbott Announces Approval of First Fully-Automated Blood Screening Test for Hepatitis C Antibodies
|
(Abbott Laboratories)
|
12-Jul-2007 |
| Sucampo Pharmaceuticals Submits Supplemental New Drug Application for Lubiprostone to Treat Irritable Bowel Syndrome with Constipation
|
(Sucampo Pharmaceuticals)
|
12-Jul-2007 |
| Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
|
(Advanced Life Sciences)
|
02-Jul-2007 |
| ENDEAVOR IV Clinical Trial Meets Primary Endpoint
|
(Medtronic)
|
02-Jul-2007 |
| New Study in Journal of Pediatrics Suggests Synagis® (palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
|
(Abbott Laboratories)
|
29-Jun-2007 |
| New Study in Journal of Pediatrics Suggests Synagis(R) (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
|
(AstraZeneca)
|
29-Jun-2007 |
| Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
|
(Genentech)
|
26-Jun-2007 |
| Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
|
(Abbott Laboratories)
|
26-Jun-2007 |
| Abbott’s RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe
|
(Abbott Laboratories)
|
21-Jun-2007 |
| Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
|
(Advanced Life Sciences)
|
21-Jun-2007 |
| Three Studies Suggest Abbott's HUMIRA® (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
|
(Abbott Laboratories)
|
15-Jun-2007 |
| Aurobindo Gets USFDA Approval for Trandolapril Tablets
|
(Aurobindo Pharma)
|
15-Jun-2007 |
| Lupin Receives Final FDA Approval for Trandolapril
|
(Lupin)
|
14-Jun-2007 |
